AI Article Synopsis
Article Abstract
It was known that d(CG)(6) became left-handed Z-DNA by a theoretical calculation. We carried out a CD measurement of d(CG)(6) at room temperature. B-Z transition was occurred when I raised the concentration of Mg salt. In addition, I confirmed that the Mg salt concentration caused B-Z transition by the lower concentration under the existence of cobalt hexamine. Structure of d(TA)(6) is not known. We performed the CD measurement of d(TA)(6) at low temperature. Structure changed from B type when I raised the Mg salt concentration in an existence of cobalt hexamine. I am examining structure now.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/nass/nrl113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Computational Simulation and Biophysical Study on Cerium Chloride-Induced B-to-Z Transition in (CG) DNA.
ACS Omega
November 2024
DNA Nanomaterials & Application Laboratory, Environment and Sustainability Department, CSIR-Institute of Minerals & Materials Technology, Bhubaneswar 751 013, India.
Rare earth elements have been shown to trigger the B-to-Z DNA transition in diverse self-assembled branched DNA architectures. Herein, we investigated the influence of cerium chloride on the conformational changes of DNA sequences containing repeated cytosine-guanine (CG) or guanine-cytosine (GC) sequences. The CD results show that (CG) repeats were susceptible to the formation of Z-DNA at low concentrations of CeCl.
View Article and Find Full Text PDFOutcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases.
Therap Adv Gastroenterol
October 2024
Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Kálvária Avenue 57, Szeged H-6725, Hungary.
Article Synopsis
- The study investigates the effectiveness, safety, and patient preferences associated with switching from intravenous to subcutaneous vedolizumab treatment for inflammatory bowel diseases over a 52-week period.
- A total of 70 patients were included, with high rates of clinical and biochemical remission observed in both ulcerative colitis and Crohn's disease groups, while 17.1% discontinued the treatment primarily due to loss of response.
- Overall, switching to subcutaneous administration showed effective treatment persistence, stable remission rates, and no new safety concerns.
Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.
Transl Lung Cancer Res
September 2024
Department of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: Emerging evidence has underscored the crucial role of infiltrating immune cells in the tumor immune microenvironment (TIME) of non-small cell lung cancer (NSCLC) development and progression. With the implementation of screening programs, the incidence of early-stage NSCLC is rising. However, the high risk of recurrence and poor survival rates associated with this disease necessitate a deeper understanding of the TIME and its relationship with driver alterations.
View Article and Find Full Text PDFMitochondrial Ca controls pancreatic cancer growth and metastasis by regulating epithelial cell plasticity.
bioRxiv
August 2024
Department of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Endoplasmic reticulum to mitochondria Ca transfer is important for cancer cell survival, but the role of mitochondrial Ca uptake through the mitochondrial Ca uniporter (MCU) in pancreatic adenocarcinoma (PDAC) is poorly understood. Here, we show that increased MCU expression is associated with malignancy and poorer outcomes in PDAC patients. In isogenic murine PDAC models, deletion ( ) ablated mitochondrial Ca uptake, which reduced proliferation and inhibited self-renewal.
View Article and Find Full Text PDFMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.
Cancer Discov
November 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Article Synopsis
- KRAS inhibitors are medicine that work against a type of pancreatic cancer called PDAC, but patients often develop resistance to these treatments.
- When patients with a specific mutation (KRASG12C) took certain drugs, new mutations and changes were found that helped the cancer resist the treatment.
- Using a mix of KRAS inhibitors and chemotherapy showed better results in controlling tumors in mouse models, suggesting that combining treatments might be a smarter approach for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!